查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1735697

全球麻疹、腮腺炎和德國麻疹病毒疫苗市場規模（按患者類型、通路、區域覆蓋範圍和預測）

Global Measles, Mumps, And Rubella Virus Vaccine Market Size By Patient Type, By Distribution Channel, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

麻疹、腮腺炎及德國德國麻疹病毒疫苗市場規模及預測

2024 年麻疹、腮腺炎和德國麻疹病毒疫苗市場規模為 8.1956 億美元，預計到 2032 年將達到 11.1303 億美元，預測期內（2026-2032 年）的複合年成長率為 3.90%。

推動全球麻疹、腮腺炎和德國德國麻疹病毒疫苗市場的因素

麻疹、腮腺炎和德國麻疹病毒疫苗市場的市場促進因素可能受到多種因素的影響，包括：

  • 政府免疫計畫：推動 MMR 疫苗需求的主要因素是各國政府對旨在遏制麻疹、腮腺炎和德國德國麻疹等感染疾病傳播的免疫宣傳活動的興趣和資金不斷增加。
  • 教育與宣傳：隨著人們越來越意識到疫苗接種的價值及其如何幫助預防某些疾病，需求可能會增加。非政府組織、政府機構和醫療保健專業人員在提高大眾對麻疹、腮腺炎和德國麻疹 (MMR) 疫苗益處的認知方面發揮著至關重要的作用。
  • 疾病發生率上升：由於世界各地爆發流行性腮腺炎和德國麻疹，疫苗接種需求增加。人們也擔心，由於某些地區的疫苗接種覆蓋率下降，這些疾病可能會再次出現，這也刺激了市場擴張。
  • 技術進步：疫苗技術的持續研發，推動了更安全、更有效的麻腮風（MMR）疫苗的研發。市場擴張得益於技術創新，例如單劑即可預防多種疾病的聯合疫苗的研發。
  • 全球化與旅行：全球旅行和全球化的增加導致了流行性腮腺炎、腮腺炎和德國德國麻疹等感染疾病的傳播，因此對於旅行者和交通繁忙地區的居民來說，接種疫苗至關重要。
  • 公共衛生緊急情況：疫苗可預防的疾病爆發，例如疫情和疫情，更加重視免疫接種計劃，並導致對 MMR 疫苗接種的需求增加。
  • 政府法規和法律：MMR 疫苗的需求受到政府關於上學和前往某些國家旅行所需接種疫苗的嚴格法律和規定的推動。
  • 投資醫療保健基礎設施：投資醫療保健基礎設施將改善免疫服務的可近性，並增加對 MMR 疫苗的需求，尤其是在新興經濟體。

限制全球麻疹、腮腺炎和德國德國麻疹病毒疫苗市場的因素

麻疹、腮腺炎和德國德國麻疹疫苗市場面臨許多限制和挑戰，包括：

  • 錯誤訊息和疫苗猶豫：由於錯誤訊息和對疫苗的有效性、安全性和可能的​​副作用的擔憂，這可能導致疫苗接種率下降和 MMR 疫苗市場萎縮。
  • 供應鏈挑戰：複雜的供應鏈和物流挑戰可能會阻礙 MMR 疫苗的取得和接種，包括疫苗分發和儲存所需的低溫運輸，尤其是在農村和資源貧乏地區。
  • 生產成本高：MMR 疫苗的可負擔性和可用性可能會受到疫苗生產高成本（尤其是在中低收入國家）以及嚴格的監管限制和品管標準的限制。
  • 全球經濟不確定性：景氣衰退、貨幣波動和醫療支出預算限制可能會導致 MMR 疫苗需求下降，這將影響政府、醫療保健提供者和個人對疫苗的負擔能力。
  • 疫苗研發障礙：新型或改良 MMR 疫苗的市場進入可能會受到許多障礙的限制，包括漫長的研發時間、監管障礙以及持續研究和創新的需要。
  • 競爭環境：疫苗製造商（包括老牌企業和新進業者）之間的競爭非常激烈，這可能導致定價壓力和利潤率下降，從而可能阻礙市場擴張和研發支出。
  • 法律與監管障礙：這些障礙包括專利挑戰、智慧財產權、監管核准程序等，可能會阻礙新疫苗進入市場或延遲新免疫接種的推出，進而影響整個 MMR 疫苗市場的成長。
  • 倫理和文化因素：實現較高的流行性腮腺炎-德國德國麻疹疫苗接種覆蓋率可能會受到倫理問題、文化觀點、宗教對疫苗接種的反對等因素的阻礙。這些因素可能會影響疫苗的接受度和接種率，尤其是在某些地區和社區。

目錄

第 1 章全球麻疹、腮腺炎和德國德國麻疹病毒疫苗市場簡介

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

4. 全球麻疹、腮腺炎和德國麻疹疫苗市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5. 全球麻疹-腮腺炎-德國德國麻疹疫苗市場（依患者類型）

  • 概述
  • 兒科患者
  • 成年患者

6. 全球麻疹、腮腺炎和德國麻疹病毒疫苗市場（依通路）

  • 概述
  • 醫院藥房
  • 藥局
  • 零售藥局
  • 疫苗接種中心

7. 全球麻疹-腮腺炎-德國德國麻疹疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

8. 全球麻疹、腮腺炎和德國德國麻疹疫苗市場的競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第9章 公司簡介

  • MedImmune
  • Johnson & Johnson Private Limited
  • Merck & Co., Inc
  • Sanofi
  • Serum Institute of India Pvt. Ltd
  • Bavarian NordicAstellas Pharma India Private Limited
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • JC Medical

第10章 附錄

  • 相關調查
簡介目錄
Product Code: 35927

Measles, Mumps, And Rubella Virus Vaccine Market Size And Forecast

Measles, Mumps, And Rubella Virus Vaccine Market size was valued at USD 819.56 Million in 2024 and is projected to reach USD 1113.03 Million by 2032, growing at a CAGR of 3.90 % during the forecast period 2026-2032.

Global Measles, Mumps, And Rubella Virus Vaccine Market Drivers

The market drivers for the Measles, Mumps, And Rubella Virus Vaccine Market can be influenced by various factors. These may include:

  • Government Immunisation Programmes: A major factor driving up demand for MMR vaccines is governments' increased attention to and funding of immunisation campaigns aimed at stopping the spread of infectious diseases including the measles, mumps, and rubella.
  • Growing Education and Awareness: As people become more aware of the value of immunisation and how it helps avoid certain diseases, demand will rise. One of the most important roles in raising public awareness of the advantages of the MMR vaccine is the work done by NGOs, government organisations, and healthcare professionals.
  • Increasing Disease Incidence: The need for vaccinations is being driven by measles, mumps, and rubella outbreaks in different parts of the world. Market expansion is also fueled by worries about these illnesses' potential to resurface as a result of falling vaccination rates in some areas.
  • Technological Advancements: Ongoing research and development in vaccine technology results in the creation of MMR vaccines that are safer and more effective. Market expansion is aided by innovations like the creation of combination vaccinations, which provide protection against several illnesses with a single dose.
  • Globalisation and Travel: As a result of increased worldwide travel and globalisation, infectious diseases such as measles, mumps, and rubella are spreading, making immunisation against these diseases essential for travellers and residents of high-travel regions.
  • Public Health Emergencies: When diseases that are vaccine-preventable, like pandemics or outbreaks, occur, the demand for MMR vaccinations rises as a result of the emphasis placed on immunisation programmes.
  • Government Mandates and Laws: The demand for MMR vaccines is driven by governments' strict laws and mandates pertaining to vaccination requirements for school enrollment or travel to specific countries.
  • Investments in Healthcare Infrastructure: Investing in healthcare infrastructure increases access to immunisation services, which in turn increases demand for MMR vaccines. This is particularly true in emerging economies.

Global Measles, Mumps, And Rubella Virus Vaccine Market Restraints

Several factors can act as restraints or challenges for the Measles, Mumps, And Rubella Virus Vaccine Market. These may include:

  • Misinformation and Vaccine Hesitation: One major obstacle is vaccine hesitation, which is stoked by false information and worries about the efficacy, safety, and possible side effects of vaccines. Lower vaccination rates and a decline in the market for MMR vaccinations may result from this.
  • Supply Chain Difficulties: Especially in rural or resource-poor locations, the availability and accessibility of MMR vaccines may be hampered by complicated supply chains and logistical difficulties, such as the need for cold chain conditions for vaccine distribution and storage.
  • High Manufacturing Costs: The price and accessibility of MMR vaccines may be restricted due to the high cost of manufacturing vaccines, especially in low- and middle-income countries, as well as strict regulatory regulations and quality control standards.
  • Global Economic Uncertainty: Decreases in demand for MMR vaccines can result from economic downturns, currency changes, and budgetary limits in healthcare spending that affect the affordability of vaccines for governments, healthcare providers, and individuals.
  • Obstacles in the Development of Vaccinations: The market availability of novel and enhanced MMR vaccinations may be restricted by obstacles in the form of lengthy development schedules, regulatory barriers, and the requirement for ongoing research and innovation.
  • Competitive Environment: High levels of rivalry among vaccine producers, including both long-standing firms and recent arrivals, can lead to pressure on prices and narrowed profit margins, which impedes market expansion and R&D spending.
  • Legal and Regulatory Barriers: These obstacles, which include patent battles, intellectual property rights, and regulatory approval procedures, can impede the entry of new vaccines into the market or postpone the launch of new vaccinations, which can have an impact on the MMR vaccine market's overall growth.
  • Ethical and Cultural Factors: Obtaining high vaccination coverage rates for measles, mumps, and rubella can be hampered by ethical concerns, cultural views, and religious objections to vaccination. These factors can especially affect vaccine acceptance and uptake in certain communities or areas.

Global Measles, Mumps, And Rubella Virus Vaccine Market Segmentation Analysis

The Global Measles, Mumps, And Rubella Virus Vaccine Market are Segmented on the Patient Type, Distribution Channel, and Geography.

Measles, Mumps, And Rubella Virus Vaccine Market, By Patient Type

  • Pediatric Patient
  • Adult Patient

Based on Patient Type, the market is segmented into Pediatric Patient and Adult Patient. Pediatric vaccines are given in two dosages. First at 15 years old months and the second is before the age of six. Pediatric vaccines are more viable than adult vaccines. The adult vaccines are just a solitary portion of vaccination. As per CDC, grown-ups brought into the world in 1957 or later who have not been immunized or have not had measles are suggested one portion of the measles vaccine. The pediatric vaccine portion is assessed to represent a significant portion of the worldwide Measles, Mumps, And Rubella Virus Vaccine Market.

Measles, Mumps, And Rubella Virus Vaccine Market, By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Vaccination Center

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores, Vaccination Center, and Retail Pharmacies. Vaccination centers are the most trusted channel for vaccination after that people prefer hospital pharmacies for vaccinations.

Measles, Mumps, And Rubella Virus Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, the global Measles, Mumps, And Rubella Virus Vaccine Market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the main share in the Measles, Mumps, And Rubella Virus Vaccine Market. A key factor driving the development of the market in the area is far-reaching government drives for vaccination against viral sicknesses. The Asia Pacific is arising as a critical district in the Measles, Mumps, And Rubella Virus Vaccine Market. Rising mindfulness among people of low monetary layers in agricultural nations of the district is a key factor impelling the measles, mumps, and rubella antibody market in the area.

Key Players

  • The major players in the Measles, Mumps, And Rubella Virus Vaccine Market are:
  • MedImmune
  • Johnson & Johnson Private Limited
  • Merck & Co. Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Bavarian NordicAstellas Pharma India Private Limited
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • JC Medical

Key Developments

  • In August 2021, Researchers from South Africa started a clinical experiment to see if the MMR vaccine for children may shield front-line medical staff from the Covid-19 virus or lessen the severity of the disease for individuals who contract it. Scientists from the Universities of the Witwatersrand (UW) and Cape Town (UCT) in South Africa started the trials.
  • In August 2021, GSK applied for PRIORIX (Measles, Mumps, and Rubella Virus Vaccine, Live) to be used in active immunization against measles, mumps, and rubella (MMR) infection by submitting an application for a biologic license (BLA) with the US Food and Drug Administration (FDA).
  • Ace Matrix Analysis
  • The ace matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the global Measles, Mumps, And Rubella Virus Vaccine Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the global Measles, Mumps, And Rubella Virus Vaccine Market, gauge the attractiveness of a certain sector, and assess investment possibilities

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET, BY PATIENT TYPE

  • 5.1 Overview
  • 5.2 Pediatric Patient
  • 5.3 Adult Patient

6 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
  • 6.2 Hospital Pharmacies
  • 6.3 Drug Stores
  • 6.4 Retail Pharmacies
  • 6.5 Vaccination Center

7 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East And Africa

8 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 MedImmune
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Johnson & Johnson Private Limited
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Merck & Co., Inc
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Sanofi
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Serum Institute of India Pvt. Ltd
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Bavarian NordicAstellas Pharma India Private Limited
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 CSL Limited
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Emergent BioSolutions Inc.
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 GlaxoSmithKline plc
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 JC Medical
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Appendix

  • 10.1 Related Research